Adverse event case processing is an enormous cost center and compliance issue for life sciences. As revenues stagnate for many pharma companies and profits come under new pressures, the expectation to improve its operational efficiency is substantial. But that cannot be at the expense of quality, or patient safety – the very purpose of pharmacovigilance. Organizations and their PV service providers have no choice but to take a smarter approach, underpinned by artificial intelligence and advanced automation. The cost and risk management benefits are clear, while the wider gains will include a more proactive PV operation, says Qinecsa’s John Cogan.
read more